RE-BVS – Piemonte Repository

Sfoglia per AUTORE
GIOTTA F
Collezione AO Cuneo

Items : 6

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. in Scientific reports / Sci Rep. 2021 Jul 2;11(1):13770. doi: 10.1038/s41598-021-92774-z.

2021
AO Cuneo

Pizzuti L; Barba M; Mazzotta M; Krasniqi E; Maugeri-Saccà M; Gamucci T; Berardi R; Livi L; Ficorella C; Natoli C; Cortesi E; Generali D; La Verde N; Cassano A; Bria E; Moscetti L; Michelotti A; Adamo V; Zamagni C; Tonini G; Sergi D; Marinelli D; Paoletti G; Tomao S; Botticelli A; Marchetti P; Tinari N; Grassadonia A; Valerio MR; et alii...

PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2(+) Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2020 Nov 15;26(22):5843-5851. doi: 10.1158/1078-0432.CCR-20-1731. Epub 2020 Aug 25.

2020
AO Cuneo

Urso L; Paré L; Curtarello M; Griguolo G; Orvieto E; Piacentini F; Nanni O; Cagossi K; Bertone E; Garrone O; Rimanti A; Giotta F; Musolino A; Frassoldati A; Cavanna L; Brandes AA; Bisagni G; Dieci MV; Guarneri V; Chic N; D'Amico R; Prat A; Conte P;

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. in Journal of experimental & clinical cancer research : CR / J Exp Clin Cancer Res. 2020 Dec 10;39(1):279. doi: 10.1186/s13046-020-01797-3.

2020
AO Cuneo

Del Medico P; Cazzaniga M; Garufi C; Sarobba G; Giotta F; Paris I; Garrone O; Veltri E; Corsi D; D'Ostilio N; Fabbri MA; Russo A; Mirabelli R; Valerio MR; Marchetti P; Tomao S; Marinelli D; Mazzotta M; Barchiesi G; Zamagni C; Tonini G; Adamo V; Michelotti A; Moscetti L; Bria E; Cassano A; La Verde N; Generali D; Cortesi E; et alii...

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial. in BMC medicine / BMC Med. 2019 Nov 21;17(1):207. doi: 10.1186/s12916-019-1445-z.

2019
AO Cuneo
AOU Città della Salute di Torino

Conte PF; Guarneri V; Griguolo G; D'Amico R; Vicini R; Balduzzi S; Foschini MP; Moretti G; Amaducci L; Bazan V; Romito S; Gambaro AR; Sarti S; Ferro A; Cagossi K; Danese S; Piacentini F; Soto Parra H; Zamagni C; Beano A; Rimanti A; Donadio M; Garrone O; Musolino A; Gebbia V; Aieta M; Giotta F; Cavanna L; Frassoldati A; et alii...

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2019 Mar 1;30(3):418-423. doi: 10.1093/annonc/mdz007.

2019
AO Cuneo

Miglietta F; Orvieto E; Sanders M; Maiorana A; Piacentini F; Ferro A; Sarti S; Cagossi K; Bertone E; Garrone O; Rimanti A; Giotta F; Cavanna L; Musolino A; Frassoldati A; Brandes AA; Bisagni G; Conte P; Dieci MV; Balduzzi S; D'Amico R; Guarneri V;

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2018 Dec 1;29(12):2328-2333. doi: 10.1093/annonc/mdy414.

2018
AO Cuneo
AOU Città della Salute di Torino

Vicini R; Amaducci L; Bajardi EA; Beano A; Schirone A; Lombardo L; Moretti G; Giovanardi F; Pronzato P; Russo A; Cagossi K; Rimanti A; Zamagni C; Danese S; Maltoni R; Ferro A; Musolino A; Molino A; Gebbia V; Aieta M; Giotta F; Cavanna L; Piacentini F; Garrone O; Donadio M; Brandes AA; Bisagni G; Frassoldati A; Conte P; et alii...